1084801-91-1

Basic information

• Product Name: Methyl 2-fluoro-5-hydroxybenzoate
• Synonyms: Methyl 2-fluoro-5-hydroxybenzoate
• CAS NO: 1084801-91-1
• Molecular Formula: C₈H₇FO₃
• Molecular Weight: 170.1377832
• Mol File: 1084801-91-1.mol
• Article Data: 5

Chemical Properties

• Boiling Point: 290.7±25.0 °C(Predicted)
• Appearance: /
• Density: 1.309±0.06 g/cm3(Predicted)
• Storage Temp.: Sealed in dry,Room Temperature
• PKA: 9.16±0.18(Predicted)
• CAS DataBase Reference: Methyl 2-fluoro-5-hydroxybenzoate(CAS DataBase Reference)
• NIST Chemistry Reference: Methyl 2-fluoro-5-hydroxybenzoate(1084801-91-1)
• EPA Substance Registry System: Methyl 2-fluoro-5-hydroxybenzoate(1084801-91-1)

Safety Data

• Hazardous Substances Data: 1084801-91-1(Hazardous Substances Data)

Usage

General Description

Methyl 2-fluoro-5-hydroxybenzoate is a chemical compound with the formula C8H7FO3. It is a derivative of salicylic acid and is commonly used in the synthesis of pharmaceuticals and agrochemicals. The presence of a fluoro group in its structure makes it useful in medicinal chemistry and drug development, as fluoro compounds are known for their bioactivity and metabolic stability. The hydroxy group also adds to its potential as a pharmaceutical ingredient by providing opportunities for hydrogen bonding and interactions with biological enzymes and receptors. Methyl 2-fluoro-5-hydroxybenzoate is considered a valuable building block in the production of various bioactive molecules and has significant potential for further research and application in the pharmaceutical and agricultural industries.

Upstream product

• 127667-01-0 2-fluoro 5-methoxybenzonitrile 
• 67-56-1 methanol 
• 51446-30-1 2-fluoro-5-hydroxybenzoic acid 

Relevant articles and documents

NOVEL INHIBITORS OF MAP4K1

The invention relates to novel inhibitors of MAP4K1 (HPK1) useful for the treatment of diseases or disorders characterised by dysregulation of the signal transduction pathways associated with MAPK activation, including hyperproliferative diseases, diseases of immune system dysfunction, inflammatory disorders, neurological diseases, and cardiovascular diseases. The invention further relates to pharmaceutical compositions comprising the same and methods of treatment of said diseases and disorders. The inhibitors are of formula (I) wherein the definitions for A, D, E, F, R5, R6, R7, Z, ring Q, n, x and y are as given in the application.

Synthesis, structure-activity relationships, and biological evaluation of a series of benzamides as potential multireceptor antipsychotics

In the present study, a series of benzamides, endowed with potent dopamine D2, serotonin 5-HT1A and 5-HT2A receptors properties, was synthesized and evaluated as potential antipsychotics. Among them, 3-(4-(4-(6-fluorobenzo[d]isoxazol-3-yl)-piperidin-1-yl)butoxy)-N-methylbenzamide (21) and its fluoro-substituted analogue (22) held the best pharmacological binding profiles. They not only presented potent activities for D2, 5-HT1A, and 5-HT2A receptors, but were also endowed with low activities for 5-HT2C, H1 receptors and hERG channels, suggesting a low propensity of inducing weight gain and QT prolongation. In animal models, compounds 21 and 22 reduced phencyclidine-induced hyperactivity with a high threshold for catalepsy induction. It thus provides potential candidates for further preclinical studies.

POLY (ADP-RIBOSE) POLYMERASE INHIBITOR

Disclosed are a phthalic hydrazide (phthalazine ketone) compound, and a pharmaceutical composition comprising the same. As a DNA repair enzyme poly (ADP-ribozyme) polymerase inhibitor, the compound and the pharmaceutical composition can effectively treat diseases involving PARP enzymatic activity, including cancer, neural degenerative diseases, inflammation and the like.